Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
Based on this MCDA, the high value contribution of FTD/TPI + BEVA suggests its substantial benefits over the most used alternatives.
Authors
- Carles Pericay (ORCID: https://orcid.org/0000-0002-4975-7851)
- Élena Elez (ORCID: https://orcid.org/0000-0002-4653-6324)
- Ruth Graefenhain
- Candela Calle (ORCID: https://orcid.org/0000-0003-0498-8290)
- José Luís Zamora Manzano (ORCID: https://orcid.org/0000-0002-8987-4577)
- Luís Lizán (ORCID: https://orcid.org/0000-0001-6039-2454)
- E. Moreno (ORCID: https://orcid.org/0000-0001-6752-873X)
- Asís Ariznavarreta
Institutions
- Outcomes Research Consortium (US)
- Hospital de Sant Pau (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Mútua Terrassa (ES)
- Fundació Salut i Envelliment UAB (ES)
- Servier (Spain) (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1080/20523211.2025.2567970
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00